MHLW Scratching Head over High-Price Drug Issue, Lecanemab in Mind: Bureau Chief

Kazuhito Ihara, Director-General, Health Insurance Bureau, MHLW With the filing of Eisai’s Alzheimer’s treatment lecanemab reigniting discussions on how to deal with expensive drugs in Japan, a senior health ministry official responsible for reimbursement policies admits that it is “a...read more